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In 2017 an estimated 71 million people globally were hepatitis C 
virus (HCV) viraemic, while 2.3 million were HIV co-infected.[1] 
HCV is a leading cause of cirrhosis and hepatocellular carcinoma 
(HCC) worldwide.[2] Traditionally HCV transmission has mostly been 
parenteral, typically in people who inject drugs (PWID), but recent data 
have demonstrated that HCV prevalence increased by 15 - 20% in HIV-
infected men who have sex with men (MSM) between 2007 and 2008. [3] 
Supporting these findings are reports from the USA, Australia and 
Eastern Europe of HCV emerging as a sexually transmitted infection 
among MSM. Data from the UK Public Health Service in 2012 noted 
HIV notifications increasing by 24% among MSM, of whom 13% were 
HCV co-infected.[4] In 2015, HCV accounted for almost 38 000 deaths 
in sub-Saharan Africa.[5] However, there are few data for high-risk 
groups, with accurate data collection complicated by potential cultural 
bias and laws against PWID and MSM. Approximately 8% of the global 
PWID population resides in sub-Saharan Africa, and hepatitis C is 
incompletely characterised in this key population.[6]
The genotype distribution of HCV in a population is informative, 
and the finding of predominantly genotypes 1 and 4 in non-PWID 
MSM and genotype 3a in PWID suggests possible intra-network 
modes of transmission.[7]
South Africa (SA) is an epicentre of the HIV pandemic, with an 
estimated 12.2% HIV prevalence equating to some 7.1 million HIV-
infected people.[8] There are very few data on HCV and HCV-HIV 
co-infection prevalence in SA. Data from blood transfusion services 
indicate donor HCV viraemic rates of ≤0.3% and random clinic-
based screening data reporting 1% seroprevalence rates. Of note, in 
a 1997 antiretroviral therapy study with mandatory HCV screening 
that included SA as a site, HCV antibody prevalence in HIV-positive 
patients was 2%, much higher than would have been anticipated.[9] 
Local HIV management guidelines do not include routine screening 
for HCV. A concern with HIV/HCV co-infection is that it can 
accelerate the progression of liver disease and HCC risk.[10]
Objectives
Given the need for the better understanding of our local HCV 
epidemiology, we elected to determine local HCV prevalence in an 
at-risk group, viz. HIV-positive men, by comparing heterosexual men 
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Background. Globally 1% of individuals are infected with hepatitis C virus (HCV). In South Africa (SA) the prevalence ranges between 
0.3% and 1%, with few prospective screening data available. Similarly, local data on transmission modes of HCV are limited, but probably 
include parenteral routes and pre-1992 blood or blood products. The risk of heterosexual transmission of HCV is low but is increased in 
men who have sex with men (MSM), with co-transmission risk of both HIV and HCV.
Objectives. Given few local data, we sought to better understand HCV characteristics and prevalence in two groups of HIV-infected men.
Methods. HIV-positive men in the greater Cape Town metropolitan area were recruited. Sexual orientation was self-identified and 
demographic and other personal data were obtained via a confidential questionnaire. Participants were screened for HCV after a 
blood draw. Those with positive HCV tests had further HCV RNA confirmation. Risk factors associated with HCV seropositivity were 
determined.
Results. Five hundred HIV-positive men were recruited, 285 (57.0%) MSM and 215 (43.0%) non-MSM, median age 36 years (interquartile 
range (IQR) 20 - 64) and 37 years (IQR 21 - 56), respectively (p=NS). Overall, 3.4% (n=17) screened HCV-positive, 5.6% MSM (n=16) and 
0.5% non-MSM (n=1); 82.4% were viraemic for HCV RNA. In respect of genotype distribution, 50.0% were infected with genotype 1a, 14.3% 
with genotype 4 and 35.7% with genotype 2. In terms of risk, MSM were more likely to have used drugs (54.4% v. 30.2%; p<0.001) and to 
have used all five modes of drug administration (13.0% MSM v. 0.5% non-MSM for injected drugs, 36.1% v. 2.3% for inhaled, 10.0% v. 0% for 
rectal, 48.1% v. 28.8% for smoked and 27.4% v. 2.3% for oral). More MSM than non-MSM (46.3% v. 16.7%) reported having sex while using 
recreational drugs, and similarly more MSM (21.4% v. 14%) reported having sex with a sex worker (SW). Risk factors for HCV seropositivity 
included drug use history (odds ratio (OR) 6.28, 95% confidence interval (CI) 1.78 - 22.12; p=0.004) and in MSM, sex with an SW (OR 5.5, 
95% CI 2.06 - 14.68; p=0.001) or use of recreational drugs with sex (OR 6.88, 95% CI 2.21 - 21.44; p=0.001).
Conclusions. HCV prevalence in HIV-positive MSM is higher than previously appreciated or documented in SA. Risk factors include 
injection drug use, use of recreational drugs with sex, and sex with SWs. Targeted interventions are required to address this emerging 
challenge to achieve the viral hepatitis elimination ideal by 2030.
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and MSM, to better characterise modes of transmission and HCV 
genotype distribution.
Methods
Study design
Serologically confirmed HIV-positive men aged >18 years were 
prospectively recruited between 2011 and 2014 from healthcare 
centres in the greater Cape Town metropolitan area, including 
a dedicated clinic serving MSM. Following informed consent, 
participants self-identified their sexual orientation as heterosexual 
or MSM. A confidential questionnaire was administered during a 
face-to-face interview. Blood samples were obtained for testing and 
storage at –80oC within an hour of collection. Serum was tested for 
the presence of hepatitis C IgG antibody using the ARCHITECT II 
system (Abbott Diagnostics Division, USA). Samples positive for 
hepatitis C IgG antibody were analysed for the presence of hepatitis 
C RNA by means of an in-house polymerase chain reaction (PCR) 
technique after amplifying the 5’NCR region of the virus. HCV 
genotype was determined using the Versant HCV Genotype v2.0 
Line Probe Assay (Siemens AG, Germany) and viral loads using 
the COBAS Ampliprep/Cobas TaqMan v2.0 (Roche Diagnostics, 
Switzerland). All participants identified as viraemic for HCV were 
referred to the Liver Clinic at Groote Schuur Hospital, Cape Town. 
The Human Research Ethics Committee of the Faculty of Health 
Sciences, University of Cape Town, approved the study (ref. no. 355/ 
2009). The study complied with the Declaration of Helsinki (2007).
Data collection
A standardised structured questionnaire that included demographic 
data was confidentially administered to all participants to capture 
information on age, self-identified ethnicity/race and sexual orienta-
tion, and other risk factors for HCV acquisition, e.g. blood transfu-
sion/blood products received prior to 1992. A detailed history of past 
or current substance use was obtained, including cannabis, MDMA 
(methylenedioxymethamphetamine), GHB (gamma- hydroxybutyr-
ate), crystal methamphetamine, cocaine, CAT (methcathinone), 
liquid MDMA (liquid E), heroin and methaqualone. The mode of 
substance use administration was recorded as oral, sniffing/insuf-
flation, injection, smoking or rectal, and the quantity of alcohol 
consumed (g/d) was also documented. Information on the use of 
these substances at times of sexual intercourse and on the use of 
commercial sex worker (SW) services was also recorded. Additional 
data including possible needlestick injury (especially for healthcare 
workers) and known hepatitis B surface antigen status and CD4+ 
counts were documented.
Statistical analysis
The non-MSM and MSM groups were compared and statistical 
significance was tested at a level of 0.05 with 95% confidence intervals 
(CIs). Medians and interquartile ranges (IQRs) were reported for 
measured data (age and CD4+ count) as they were not normally 
distributed, while frequencies and percentages were used to describe 
categorical data. The χ2 test was used to compare categorical 
outcomes and the Wilcoxon rank-sum test to compare measured 
data. HCV prevalence as reported by antibody and viraemia was 
calculated as a simple proportion of HCV-positives divided by the 
whole sample. Exploratory univariate analysis for factors associated 
with acquiring HCV infection was performed. The use of individual 
drugs (cannabis, MDMA, GHB/liquid E, crystal meth, cocaine, 
CAT, heroin and methaqualone) and drug administration modes 
(oral, sniffing, injection, smoking and rectal) were also explored for 
association with acquiring HCV. Other variables considered were 
previous parenteral injury for former or current healthcare workers, 
sexual history variables such as whether the individual was in a 
current relationship or not, current sex partner, MSM v. non-MSM, 
drug use before or during sex, and sex with a commercial SW. Odds 
ratios (ORs) and their 95% CIs were reported. Statistical analysis was 
performed using Stata 15 (StataCorp, USA).
Results
Demographic characteristics
Table 1 provides a summary of the demographics of the study 
participants. Of the 500 HIV-positive men recruited, 285 (57.0%) were 
MSM and 215 (43.0%) non-MSM. The median ages of the MSM and 
the non-MSM were 36 years (IQR 20 - 64) and 37 years (IQR 21 - 56) 
(p=NS). The median CD4+ T-cell count of the MSM was significantly 
higher than that of the non-MSM, 413 cells/µL (IQR 78 - 989) and 
283 cells/µL (IQR 7 - 727), respectively; p<0.001. Most non-MSM 
participants (88.8%) were black African, while most MSM (48.1%) 
were white. There were no differences in pre-1992 blood/blood 
product exposure between MSM and non-MSM. MSM were more 
likely to have used drugs (54.4% v. 30.2%, p<0.001). Furthermore, 
MSM were more likely than non-MSM to have used all five modes of 
drug administration (p<0.001). MSM were also more likely to have 
used cannabis, GHB, MDMA, crystal meth, cocaine, CAT or heroin. 
No participant gave a history of a needlestick injury. Non-MSM were 
more likely than MSM to be in a monogamous relationship (76.3% v. 
42.1%; p<0.001). A small component of MSM (2.3%) reported women 
as their predominant sexual partners, while 7.8% reported having 
both males and females as their normal sexual partners. Of the MSM, 
46.3% reported having sex under the influence of recreational drugs, 
compared with 16.7% of non-MSM (p<0.001), while 21.4% of MSM 
reported having sex with a commercial SW, compared with 14.0% 
of non-MSM (p=0.033). Significantly more non-MSM than MSM, 
26.1% and 18.3%, respectively, reported alcohol consumption of ≥40 
g/day (p=0.036). Hepatitis B surface antigen status did not differ 
significantly between MSM and non-MSM (p=0.064).
HCV prevalence
In total, 3.4% (n=17) were HCV IgG antibody-positive at screening 
(Table 2), the majority in the MSM group (5.6% of MSM (n=16) and 
0.5% of non-MSM (n=1)). Non-MSM who screened HCV antibody-
positive reported only inhaled heroin use and no other drug use. Of 
the MSM who screened positive, 14 were HCV PCR-positive and 
3 negative, yielding a viraemia rate of 2.8%. In respect of genotype 
distribution, 50.0% were genotype 1a, 14.3% genotype 4 (subtype 
4d) and 35.7% genotype 2 (subtypes 2b or 2c). The median HCV 
viral load was 538 500 IU/mL (range 19 000 - 1 400 000). Of those 
who screened HCV-positive, a single participant reported using a 
significant amount of alcohol (≥40 g/d).
Risk factors for HCV
Factors associated with an increased risk of acquiring HCV infection 
are listed in Table 3. White race, low CD4+ count and use of drugs 
were strongly associated with risk. This was irrespective of the type of 
drug used or route of administration. Use of drugs with sex and sex 
with an SW were associated with equal risks of being HCV-positive.
Discussion
The overall HCV seroprevalence in HIV-positive men was 3.4%, 
notably higher than previously reported in SA. However, MSM 
constituted the overwhelming majority of those who screened 
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HCV-positive. This is in keeping with data supporting MSM as 
an emerging at-risk population. Our study is the first prospective 
screening study of its kind in SA specifically looking at this key 
demographic. A recent systematic review of HCV seroprevalence 
in the sub-Saharan Africa region suggested a pooled HCV 
seroprevalence rate of 2.98%. When subcategorised, the HCV 
seroprevalence rate was 5.7% among HIV-infected individuals.[5,11] 
Our findings are not dissimilar. Two studies in Nigeria, based on 
hepatitis C antibody seroprevalence in different centres, 3 years apart 
and performed in heterogeneous groups of HIV-positive cohorts, 
demonstrated even higher seroprevalence rates of 10.8% and 15%, 
respectively.[12,13] Interestingly, more women tested HCV antibody-
positive. In one of the studies there was no significant correlation 
between injected drug use and HCV infection.[13] This possibly 
suggests that HIV poses a signficant risk for HCV acquisition 
regardless of gender. In this cohort, it is unclear whether the women 
were asked about their sexual risks, or whether they were screened 
for other sexually transmitted infections. In those who were HCV 
antibody-positive, 82% confirmed HCV RNA-positive, yielding an 
overall viraemic rate of 2.8%. All our viraemic patients were in the 
MSM cohort. We observed that MSM were more likely to use drugs 
and significantly more used an injection route. Existing data support 
the fact that injecting drug use is associated with increased risks of 
both HIV and HCV acquisition.[14] All participants in the MSM group 
who tested HCV antibody-positive had a history of injecting drug 
use, among other routes. The single non-MSM participant denied 
injecting drug use.
Table 1. Characteristics of MSM and non-MSM participants
Variable MSM (N=285) Non-MSM (N=215) p-value
Age (years), median (IQR) 36 (20 - 64) 37 (21 - 57) 0.627
CD4+ count (cells/µL), median (IQR) 413 (78 - 989) 283 (7 - 727) <0.001
Ethnicity, n (%) <0.001
Mixed ancestry 66 (23.2) 18 (8.4)
Black African 79 (27.7) 191 (88.8) 
White 137 (48.1) 5 (2.3)
Asian 3 (1.1) 1 (0.5)
Blood transfusion (pre-1992), % 2.8 0.9 0.138
Drug history (yes), % 54.4 30.7 <0.001
Drug routes, % <0.001
Injected 13.3 0.5
Oral 27.4 2.3
Smoked 48.1 28.8
Inhaled 36.1 2.3
Rectal 10.2 0
Drug use, %
Cannabis 39.7 27.4 0.004
MDMA 29.8 2.8 <0.001
GHB/liquid E 17.9 0.9 <0.001
Crystal meth 31.9 4.2 <0.001
Cocaine 30.9 3.7 <0.001
CAT 39.7 27.4 <0.001
Heroin 7.0 2.8 0.035
Mandrax 6.7 6.5 0.945
In a current relationship (yes), % 42.1 76.3 <0.001
Had sex under influence of drugs (yes), % 46.3 16.7 <0.001
Had sex with commercial sex worker (yes), % 21.4 14.0 0.033
Normal sex partner <0.001
Men 90.1 0
Women 2.1 100
Both 7.8 0
Alcohol intake ≥40 g/d (yes), % 18.3 26.1 0.036
Hepatitis B surface antigen 0.064
Positive 4.9 2.8
Negative 67.4 47.9
Unknown 27.7 49.3
MSM = men who have sex with men; IQR = interquartile range; MDMA = methylenedioxymethamphetamine; GHB = gamma-hydroxybutyrate; CAT = methcathinone.
Table 2. Hepatitis C infection prevalence
Screened 
positive, n
Prevalence, % 
(95% CI)
All participants (N=500) 17 3.4 (2.1 - 5.4)
MSM (N=285) 16 5.6 (3.5 - 9.0)
Non-MSM (N=215) 1 0.5 (0.06 - 3.3)
CI = confidence interval; MSM = men who have sex with men.
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An important factor associated with HCV acquisition was high-risk 
sexual behaviour. There were significant differences in numbers of 
MSM who engaged in such behaviour, namely having unprotected 
sex with commercial SWs and having sex with the use of recreational 
drugs. Several studies have shown that HCV is increasing as a 
sexually transmitted infection among MSM who do not inject 
drugs.[16,17] Several observational studies comparing injecting with 
non-injecting MSM have noted that non-injecting patients had 
different viral phylogenetic profiles compared with injectors.[18-20] 
The conclusion from this observation suggested a permucosal route 
of transmission, especially among HIV-positive MSM who had 
multiple sexual partners, MSM who tested positive for other sexually 
transmitted disease, namely syphilis, and MSM who engaged in 
sexual practices that could cause mucosal trauma, such as fisting 
and use of objects. Similarly, we observed an association between 
sex with SWs and HCV seropositivity. We observed that injecting 
drug users were seven times more likely than non-injecting drug 
users to acquire HCV infection. It is, however, thought that sexual 
behaviours that are likely to cause mucosal trauma increase the risk 
of HCV transmission.[21] These behaviours include lack of lubricant 
use, possibly douching before anal sex, multiple partners and sex 
in the context of crystal methamphetamine use. We did not record 
information on specific sexual practices of MSM in our study, other 
than determination of anal sex. We do, however, note that in our local 
experience we have observed several HCV-positive MSM without 
any reported substance use or behaviours likely to cause trauma 
to anorectal tissue, suggesting ordinary unprotected penile-anal 
sexual activity as the only risk factor for HCV transmission in often 
concomitantly HIV-positive MSM.[22]
An unexpected finding was the genotype distribution in our 
cohort. Genotype 1a predominated (50.0%), followed by genotype 2 
(35.7%) and genotype 4 (14.3%), with no genotype 3 or 5 reported. 
This contrasts with a study in the general SA population, where even 
though genotype 1 was a predominant genotype among blood donors 
(34%), genotype 5 was the most prevalent overall.[5] However, a very 
recent seroprevalence survey of key populations in SA demonstrated 
genotypes 1, 3 and 4 in MSM, PWID and SWs.[23] This suggests 
that selected genotypes are circulating in SA MSM and other key 
populations. Furthermore, given that Cape Town is a popular 
international destination, the possibility of sex tourism by MSM 
introduces the potential that dominant genotypes, e.g. genotype 2c, 
from European origins may explain this genotype predominating 
in our MSM population. Phylogenetic linkage analyses of patients 
with similar, yet uncommon genotype subtypes would suggest a 
network spread of virus. Seven of the 14 viraemic patients have been 
linked to care. They were all treated successfully, one with pegylated 
interferon/ribavirin-based therapy and all the others with the more 
recent direct-acting antiviral therapies for hepatitis C. Despite proper 
counselling during the recruiting period, 50% of HCV-viraemic 
individuals were lost to follow-up and appropriate linkage to care. 
This has serious implications, as these are high-risk individuals who 
are likely to onwardly transmit the infection. Hepatitis C is invariably 
an asymptomatic infection, and if high-risk individuals are not 
screened periodically, we will fail to identify and treat HCV-infected 
individuals and prevent onward transmission. Elimination of viral 
hepatitis in the high-risk groups of MSM and PWID requires active 
harm reduction practices including hepatitis B vaccination, condom 
use and needle-syringe and opiate substitution programmes.
Study limitations
This was a small select group that lacked heterogeneity. A larger 
number more representative of SA, including provinces more affected 
by HIV infection, may yield different HCV seroprevalence rates.
Conclusions
This study alone raises concerns that HCV seroprevalence is indeed 
underestimated in SA in at-risk populations. Key populations, 
and particularly those who are HIV-infected, should access 
HCV screening. Furthermore, all patients with the risk profiles 
described above should be tested for HCV and be linked to care. 
Without addressing infections in key populations, attainment of the 
elimination ideal for hepatitis C will not be achieved.
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Table 3. Risk factors for HCV infection
Variable
Univariate analysis
OR (95% CI) p-value
Demographics
Age 1.04 (0.995 - 1.09) 0.078
Ethnicity
Black African 1 (base)
Mixed ancestry 3.24 (0.20 - 52.38) 0.408
White 31.77 (4.15 - 243.18) 0.001
CD4+ <200 cells/µL 1.003 (1.001 - 1.005) <0.001
Drug use 
Drug use history 6.28 (1.78 - 22.12) 0.004
Cannabis use 3.67 (1.33 - 10.09) 0.012
MDMA use 4.28 (1.61 - 11.43) 0.004
GHB use 6.65 (2.42 - 18.30) <0.001
Crystal meth use 10.77 (3.70 - 31.36) <0.001
Cocaine use 3.99 (1.50 - 10.63) 0.006
CAT use 7.64 (2.84 - 20.54) <0.001
Heroin use 9.17 (2.96 - 28.41) <0.001
Mandrax use 3.24 (0.88 - 11.88) 0.077
Drug use routes
Smoking 5.19 (1.67 - 16.15) 0.004
Injection 22.35 (7.93 - 63.04) <0.001
Nasal 7.30 (2.63 - 20.22) <0.001
Oral 6.22 (2.32 - 16.63) <0.001
Rectal 7.97 (2.60 - 24.45) <0.001
Alcohol ≥40 g/d 0.22 (0.29 - 1.68) 0.144
Sexual history
In a current relationship 0.40 (0.14 - 1.11) 0.077
Current partner (male) 1.07 (0.38 - 2.97) 0.897
MSM (v. non-MSM) 12.73 (1.67 - 96.75) 0.014
Sex after drugs 6.88 (2.21 - 21.44) 0.001
Sex with CSW 5.50 (2.06 - 14.68) 0.001
Normal sex partner 0.23 (0.07 - 0.77) 0.018
 Hepatitis B surface 
antigen (positive v. 
negative)
1.53 (0.56 - 4.17) 0.405
OR = odds ratio; CI = confidence interval; MDMA = methylenedioxymethamphetamine; 
GHB = gamma-hydroxybutyrate; CAT = methcathinone; MSM = men who have sex with 
men; CSW = commercial sex worker.
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